RN276

RN276 is a preclinical small interfering RNA (siRNA) therapeutic candidate developed by Shanghai Rona Therapeutics for the treatment of Alzheimer's disease. It is designed to target the mRNA of the Microtubule-associated protein tau (MAPT), thereby silencing the expression of the Tau protein, which is a central driver of neurodegeneration when it aggregates into neurofibrillary tangles. RN276 utilizes Rona's proprietary APOLLO platform, a delivery technology engineered for extra-hepatic applications that is specifically designed to cross the blood-brain barrier (BBB). This allows the siRNA to reach the central nervous system following systemic administration, offering a potential disease-modifying approach for tauopathies by reducing the overall burden of pathological Tau in the brain.